Zachary T. Bloomgarden, MD, MACE: In individuals with liver disease, one has to be cognizant that there is a small but definite potential for abnormalities of liver chemistries with statins. By and large, individuals with chronic liver disease do tolerate statins well, although they (patients) require careful observation of liver chemistries.
In the setting of acute hepatitis, the better part of valor would be to avoid statin therapy since the statins really should be seen as long-term drugs, not drugs that must be given every moment of an individual’s lifetime.
Liver disease should be a consideration, but the minor abnormalities of liver chemistry, which occur with statin therapy, are currently seen as not representing serious clinical conditions.
With renal disease, there is a bit of evidence that very high doses of statins, particularly rosuvastatin, may have adverse effects on renal function. So, as a consequence, one needs to use these drugs with a bit of greater caution in individuals with renal insufficiency. There’s also some evidence that individuals with very advanced kidney disease at the level of dialysis or just predialysis may have attenuation of the benefit of statins in reducing cardiovascular end points. So this is a group to bear in mind, and certainly we do have to be careful in individuals with any severe chronic kidney disease (CKD) when administering statins.
But they [statins] are effective agents and we have to remember that individuals with CKD, especially those with stage 3 and higher CKD, rarely die of progression to end-stage renal disease. Rather, in those individuals, CKD is essentially a cardiovascular risk marker. As such, the prevention of cardiovascular disease, which we know statins can offer, is of much greater importance than the potential interaction. So monitor, monitor, monitor. Be careful in administering these drugs, but individuals with CKD can [absolutely] receive statins when used appropriately.
Addressing Racial Disparities in Minority Mental Health and Finding Support in 2025
July 18th 2025National Minority Mental Health Month emphasizes the persistent mental health disparities among US racial and ethnic minorities, stemming from lower access to services, lack of culturally competent providers, discrimination, and medical mistrust, underscoring the need for dedicated resources and community action.
Read More
Lung Transplant Referrals Lag for High-Risk Patients With PAH
July 18th 2025Despite recommendations on early referral for lung transplantation in cases of pulmonary arterial hypertension (PAH), there is a lack of in-depth understanding of this current landscape; in this analysis, clinical parameter data were used to compare outcomes between patients who were and were not referred for lung transplantation.
Read More